Mutant chicken interleukin-1beta protein as chicken interleukin-1beta antagonist and uses thereof

Patent metadata

Field	Value
Publication number	US-2018009867-A1
Application number	US-201615260017-A
Country	US
Kind code	A1
Filing date	Sep 8, 2016
Priority date	Jul 6, 2016
Publication date	Jan 11, 2018
Grant date	—

Abstract

The present invention provides a mutant chicken interleukin-1β protein as a chicken interleukin-1β antagonist, which has a substituted peptide at position 117 and/or 118 of wild-type chicken interleukin-1β peptides. The mutant chicken interleukin-1β protein is created by using point mutation in a method genetic engineering; it can significantly inhibit proliferation of avian virus, such as avian influenza virus, avian reovirus and Marek's disease virus, and avian inflammation response. Therefore, the mutant chicken interleukin-1β protein of the present invention can be used as antiviral and anti-inflammatory medication.

First claim

What is claimed is:

1 . A mutant chicken interleukin-1β protein, which has a substitution mutation at a position 117 and/or 118 of SEQ ID NO: 1.

2 . The mutant chicken interleukin-1β protein according to claim 1 , wherein the substitution mutation is a T117A, E118K, E118R, E118A substitution mutation of SEQ ID NO: 1.

3 . A chicken interleukin-1β antagonist, which is the mutant chicken interleukin-1β protein according to claim 1 .

4 . The chicken interleukin-1β antagonist according to claim 3 , wherein the substitution mutation is a T117A, E118K, E118R, E118A substitution mutation of SEQ ID NO: 1.

5 . A method of treating a disease caused by avian virus infection, comprising administering to a subject an effective amount of a medicament including a chicken interleukin-1β antagonist.

6 . The method according to claim 5 , wherein the chicken interleukin-1β antagonist is the mutant chicken interleukin-1β protein according to claim 1 .

7 . The method according to claim 5 , wherein the avian virus infection is avian reovirus, avian influenza virus, Marek's disease virus or Newcastle disease virus infection.

8 . The method according to claim 5 , wherein the medicament is administered via an oral route or an intravenous injection.

9 . The method according to claim 6 , wherein the mutant chicken interleukin-1β protein inhibits proliferation of avian virus and avian inflammation response.

10 . The method according to claim 6 , wherein the substitution mutation is a T117A, E118K, E118R, E118A substitution mutation of SEQ ID NO: 1.

Assignees

• Univ Nat Tsing Hua

Inventors

• Yin Hsien-Sheng
• Chen Wen-Ting

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/545 Primary

  IL-1 · CPC title

• A61P31/12

  Antivirals · CPC title